Compugen (CGEN) Projected to Post Quarterly Earnings on Monday

Compugen (NASDAQ:CGEN) is expected to post its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect Compugen to post earnings of ($0.09) per share and revenue of $1.4690 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, November 10, 2025 at 8:30 AM ET.

Compugen (NASDAQ:CGEN) last released its earnings results on Wednesday, August 6th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Compugen had a negative net margin of 87.45% and a negative return on equity of 34.77%. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $3.95 million. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compugen Stock Down 1.2%

Shares of CGEN stock opened at $1.62 on Friday. The firm has a market cap of $144.56 million, a P/E ratio of -7.36 and a beta of 2.59. The company has a 50 day moving average of $1.61 and a 200-day moving average of $1.56. Compugen has a 12-month low of $1.13 and a 12-month high of $2.66.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. bought a new stake in shares of Compugen during the second quarter valued at about $56,000. Osaic Holdings Inc. grew its stake in Compugen by 346.0% during the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 34,045 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in Compugen by 1,077.0% during the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after acquiring an additional 359,785 shares during the period. Institutional investors own 12.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CGEN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, October 8th. Wall Street Zen downgraded Compugen from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Compugen currently has a consensus rating of “Hold” and an average target price of $4.00.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.